But not me at a decade - how long ago I had ATI from these guys...

But not me at a decade - how long ago I had ATI from these guys on a lame arm. The share market is fickle, the results of OCC's treatments enduring for patients and its eventual business recognition and success.

Most micro-cap bio-techs have been utterly punished in the last two years and OCC's SP has at least endured. It seems one or two investors out there can read a balance sheet and cash flow statement.

The science works; is FDA/EMA/TGA approved; and when you take out R&D expense to get even more lucrative aspects of its science to US market, is already cash flow positive barely a year out from BioHorizons mkt release of Striate.

Roll on late January Appendix 4C. More of the same improving financial trajectory, just how much is the question....